| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
HIV-2
Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside inhibits HIV-2 RNase H with an IC₅₀ of 5.19 μM. It also shows activity against α-glucosidase with an IC₅₀ of 5.60 ± 1.57 μM. The compound targets viral enzymes essential for HIV replication. |
|---|---|
| ln Vitro |
In vitro, Kaempferol-3-O-(6″-galloyl)-β-D-glucopyranoside (compound 3; KGG) at concentrations of 12, 25, and 50 μM inhibits NLRP3 protein expression in RAW 264.7 cells. It also significantly and concentration-dependently inhibits IL-1β protein expression in these cells. The compound shows competitive inhibition against ATP in enzyme kinetics studies.
|
| ln Vivo |
In vivo activity data for Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside are limited. Based on its in vitro activity against HIV-2 RNase H and its anti-inflammatory effects, it may have potential for in vivo studies in models of viral infection or inflammation, but specific in vivo data have not been extensively reported.
|
| Enzyme Assay |
For non-cellular in vitro enzyme assays, Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside is tested against purified HIV-2 RNase H enzyme. The compound is incubated with the enzyme and a suitable substrate, and the inhibition of RNase H activity is measured to determine the IC₅₀ value of 5.19 μM. Enzyme kinetics studies may be performed to determine the mode of inhibition.
|
| Cell Assay |
For in vitro cellular assays, Kaempferol-3-O-(6″-galloyl)-β-D-glucopyranoside is tested in RAW 264.7 macrophage cells. Cells are treated with the compound at concentrations of 12, 25, and 50 μM, and the expression of NLRP3 and IL-1β proteins is assessed by Western blot or ELISA to evaluate anti-inflammatory activity.
|
| Animal Protocol |
In vivo animal studies for Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside have not been extensively documented. Based on its anti-inflammatory and antiviral properties, potential studies could involve administration to murine models of inflammation or viral infection to assess efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside are limited. As a flavonoid glycoside, it is expected to have moderate oral bioavailability, with metabolism likely involving deglycosylation in the gut or liver. The galloyl group may also be subject to hydrolysis. Further studies are needed to determine its ADME profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside are limited. As a naturally occurring flavonoid glycoside, it is generally considered to have low toxicity, but comprehensive safety evaluations would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Kaempferol 3-O-(6''-galloyl)-β-D-glucopyranoside has been reported in Myrothamnus flabellifolia, Toxicodendron sylvestre, and other organisms with available data.
Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside is a naturally occurring flavonoid glycoside that inhibits HIV-2 RNase H with an IC₅₀ of 5.19 μM. It also shows activity against α-glucosidase and exhibits anti-inflammatory effects by inhibiting NLRP3 and IL-1β expression in macrophages. The compound has a molecular weight of 600.48 and a molecular formula of C₂₈H₂₄O₁₅. |
| Molecular Formula |
C28H24O15
|
|---|---|
| Molecular Weight |
600.48
|
| Exact Mass |
600.112
|
| CAS # |
56317-05-6
|
| PubChem CID |
5491813
|
| Appearance |
Light yellow to yellow solid powder
|
| Source |
Originated from plants: Leguminosae Sophora japonica (L.) Schott
|
| LogP |
0.737
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
43
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)COC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)O)O
|
| InChi Key |
STMNAPXMGWBZSF-OAYLZIFXSA-N
|
| InChi Code |
InChI=1S/C28H24O15/c29-12-3-1-10(2-4-12)25-26(22(36)19-14(31)7-13(30)8-17(19)41-25)43-28-24(38)23(37)21(35)18(42-28)9-40-27(39)11-5-15(32)20(34)16(33)6-11/h1-8,18,21,23-24,28-35,37-38H,9H2/t18-,21-,23+,24-,28+/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~83.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (2.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6653 mL | 8.3267 mL | 16.6533 mL | |
| 5 mM | 0.3331 mL | 1.6653 mL | 3.3307 mL | |
| 10 mM | 0.1665 mL | 0.8327 mL | 1.6653 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
